Matrix reloaded to circulation hits the tumor target  by Wickström, Sara A et al.
CANCER CELL : JUNE 2003 · VOL. 3 · COPYRIGHT © 2003 CELL PRESS 513
P R E V I E W S
Tumor tissue, like normal tissue, is
dependent on functional vasculature for
sufficient supply of nutrients and oxygen.
An expanding tumor becomes rapidly
hypoxic, resulting in the activation of
hypoxia-inducible genes such as the
gene encoding vascular endothelial
growth factor (VEGF), which is secreted
from the cells and induces angiogenesis,
the formation of new capillaries from pre-
existing vessels (Ferrara, 2002). At the
cellular level, angiogenesis can be dis-
sected into events starting from endothe-
lial cell activation, subsequent degradation
of the underlying basement membrane,
migration of the cells toward the direction
of a chemotactic stimulus, and finally
reassembly and maturation of vessel
structures. The shift from a quiescent to
an angiogenic phenotype has been
described as a biological switch: an
increase in proangiogenic stimuli with
simultaneous downregulation of inhibito-
ry signals (Bergers and Benjamin, 2003).
The inhibitory signals are commonly
cryptic fragments derived from the extra-
cellular matrix by proteolytic cleavage.
These endogenous angiogenesis
inhibitors include a fragment of type
XVIII collagen C-terminal (NC1) domain
termed endostatin and the NC1 domain
of the α3 chain of type IV collagen
termed tumstatin, as well as others, such
as canstatin, arresten, and anastellin
(Kerbel and Folkman, 2002). All of these
have been shown to inhibit tumor angio-
genesis when delivered as recombinant
proteins or via viral transduction, but
their physiological roles have remained
elusive. In this issue of Cancer Cell,
Hamano and coworkers describe
enhanced tumor angiogenesis, but nor-
mal developmental angiogenesis, in
mice lacking the α3 chain of type IV col-
lagen containing the tumstatin fragment
(Hamano et al., 2003). Interestingly, tum-
statin is generated from type IV collagen
by matrix metalloprotease-9 (MMP-9), a
protease previously described as a trig-
ger of the angiogenic switch (Bergers
and Benjamin, 2003). Furthermore, its
inhibitory signals are transmitted to the
tumor endothelium via integrin αvβ3, a
molecule shown to regulate tumor angio-
genesis both positively and negatively
(Stupack and Cheresh, 2002; Reynolds
et al., 2002). In one sense, this endoge-
nous angiogenesis inhibitor, which floats
around the body fluids, would then func-
tion as tumor suppressor.
The dual role of integrins
Integrins are heterodimeric transmem-
brane receptors that bind to ligands in
the extracellular matrix or counter-recep-
tors on adjacent cells and regulate multi-
ple aspects of cell behavior (Hynes,
2002). During the process of angiogene-
sis, integrins act in coordination with
growth factors and their receptors to
promote cell migration and adhesion
(Stupack and Cheresh, 2002). Their
downstream targets consist of a number
of signaling cascades involving mole-
cules such as Src, focal adhesion
kinase, Ras, MAP kinase, the Rho family
of GTPases, and PI3 kinase (Hynes,
2002).
Endothelial cells express multiple
integrins, but endothelial cell integrins
αvβ3, αvβ5, and α5β1 are considered cen-
tral to the regulation of angiogenesis. αvβ3
and αvβ5 become dramatically induced in
activated endothelial cells in the tumor
vasculature. In addition, inhibitors of αvβ3,
and αvβ5 disrupt pathological angiogene-
sis in various model systems (Stupack
and Cheresh, 2002). α5β1 integrin is
upregulated on endothelial cells in
response to angiogenic growth factors,
and antibodies binding to this integrin
have been shown to inhibit angiogenesis
(Kim et al., 2000). However, recent data
using gene-targeted mice revealed that
the picture is not so straightforward. Mice
lacking β3 integrins have no defects in
developmental angiogenesis, but instead
display enhanced tumor angiogenesis
(Reynolds et al., 2002), suggesting that
β3 integrins can also function as negative
regulators of angiogenesis. The new
results from Hamano and coworkers now
suggest that physiological levels of circu-
lating tumstatin suppress tumor angio-
genesis through interaction with the αvβ3
integrin expressed in the tumor endotheli-
um (Hamano et al., 2003; Figure 1). This
observation might in part explain the
unexpected observation of increased
tumor angiogenesis in mice lacking the β3
integrin (Reynolds et al., 2002). Absence
of this integrin with concomitant loss of
the inhibitory effects of tumstatin would
shift the balance of pro- and antiangio-
genic factors to favor the former.
MMP-9 in angiogenesis: A switch on
and off
MMP levels are increased in the majority
of human cancers, correlating positively
with advanced tumor stage, invasive-
ness, and poor prognosis. In various
mouse models, loss of MMP-9 has been
observed to result in decreased tumori-
genesis and metastasis (Egeblad and
Werb, 2002). In the RIP1-Tag2 trans-
genic mouse model of pancreatic islet
carcinomas, MMP-9 has been shown to
induce the transition of benign carci-
noma in situ lesions into angiogenic
carcinomas via an increase in the
bioavailabilty of vascular endothelial
growth factor VEGF (Bergers and
Benjamin, 2003). Surprisingly, Hamano
et al. saw no difference in tumor growth
between MMP-9-deficient and wild-type
mice when analyzing tumors smaller
than 500 m3 in size, but when the tumors
exceeded this size, accelerated tumor
growth occurred in mice lacking MMP-9.
This was associated with reduced levels
of plasma tumstatin, and by returning to
physiological levels of plasma tumstatin
by delivery of recombinant protein, tumor
growth decreased to the level of the wild-
type mice (Hamano et al., 2003). MMP-
9-deficient mice still have relatively high
concentrations of tumstatin in their circu-
lation (141 ± 21 versus 350 ± 24 ng/ml in
wild-type mice), but the growth rate of
the tumors in these mice did not differ
from that of the tumstatin-deficient mice.
The reason for such a threshold in tum-
statin activity is unclear. Taken together,
the current data suggest that MMP-9
acts on both sides of the angiogenic
switch: via release of VEGF, it triggers
the onset of angiogenesis in tumors, thus
accelerating tumor growth, but in later
stages of tumor development, the MMP-
9-mediated turnover of basement mem-
branes releases matrix fragments with
antiangiogenic activity, resulting in the
suppression of tumor growth.
Matrix reloaded to circulation hits the tumor target
Proteolytic fragments of various components of the extracellular matrix exhibit antiangiogenic activity via interaction with
endothelial cell surface integrins. Kalluri and coworkers (Hamano et al., 2003; this issue of Cancer Cell) use gene-targeted
mice to show a physiological role for a carboxy-terminal fragment of collagen IV in the regulation of tumor angiogenesis.
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Recent advances in understanding
the complex mechanisms of tumor
angiogenesis and the dual roles of key
molecules involved in these processes
may help to explain some of the disap-
pointing results from clinical trials using
angiogenesis inhibitors that target inte-
grins or MMPs. At the same time, they
underline the importance of therapeutic
attempts that combine two or more
agents, targeting more than one process
or several cell types. In light of the results
of Hamano et al., the use of MMP
inhibitors together with matrix-derived
angiogenesis inhibitors could result in
synergistic effects. Emerging knowledge
on the apparently opposing functions of
certain regulatory matrix proteins and
their integrin receptors during different
stages of carcinogenesis prompts the
need for detailed studies to define the
optimal time points for therapeutic inter-
vention with these agents.
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Figure 1. Putative integrin-mediated signals
generated by extracellular matrix-derived
fragments tumstatin and endostatin in the
tumor endothelium
A: Tumor growth is associated with acceler-
ated turnover of extracellular matrix and
basement membranes. Increased secretion
of MMPs leads to the release of extracellular
matrix protein fragments such as tumstatin
and endostatin (Egeblad and Werb, 2002).
These fragments are delivered via the
circulation to the tumor vasculature.
B: Tumor endothelial cells express increased
levels of αvβ3 and α5β1, which facilitate the
targeting of tumstatin and endostatin selec-
tively to the developing tumor vasculature
(Kim et al., 2000; Hamano et al., 2003).
Tumstatin binds αvβ3 and inhibits endothelial
cell cap-dependent protein synthesis via
inhibition of PI3 kinase and mTOR activity
(Maeshima et al., 2002). Endostatin in turn
binds to α5β1 and inhibits endothelial cell
migration possibly via inhibition of FAK and
ERK/p38 activity and through caveolin-1-
mediated activation of Src and subsequent
inhibition of actin cytoskeleton turnover
(Rehn et al., 2001; Sudhakar et al., 2003;
Wickström et al., 2002). A pathway in which
FAK is activated by endostatin followed by
disassembly of the actin cytoskeleton has
also been described (Dixelius et al., 2002).
The findings of Hamano et al. suggest that
tumstatin released into the circulation by
MMP-9 is an important physiological suppres-
sor of tumor angiogenesis.
